相关实验视频

Updated: Jun 16, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

与早期非小细胞肺癌患者的高PD-L1表达相关的临床因素

Shuta Ohara¹, Kenichi Suda¹, Akira Hamada¹

¹Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Thoracic cancer

|September 20, 2024

概括

肺癌中的高编程细胞死亡联体1 (PD-L1) 表达,对于免疫检查点抑制剂 (ICI) 治疗至关重要,可以通过吸烟史,从18F-FDG PET/CT的SUVmax和血纤维素水平来预测.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
医疗成像医学成像

背景情况:

新辅助性免疫检查点抑制剂 (ICI) 加上化疗与单独化疗相比,显示出更好的结果,特别是在具有高编程细胞死亡配体1 (PD-L1) 表达率的患者中.
足够的瘤样本用于PD-L1生物标志物测试并不总是可以在手术前获得.
确定高PD-L1表达的预测性临床因素对于治疗选择至关重要.

研究的目的:

探索可以预测肺癌患者高PD-L1表达的临床因素.
开发一个预测模型来识别可能具有高PD-L1表达的患者.

主要方法:

对340名肺癌患者进行了肺切除 (2014-2023) 的回顾性分析,使用现有的PD-L1表达数据.
使用奇平方测试和逻辑回归来确定与高PD-L1状态相关的临床因素.
根据确定的临床参数开发了一个预测得分.

主要成果:

吸烟史,高最大标准化吸收值 (SUVmax) 在18F-氧葡萄糖正子发射计算机断层扫描 (18F-FDG PET/CT) 上,以及高血纤维素原被确定为高PD-L1表达的独立预测因素.
开发了一个预测得分 (0-3),显示高PD-L1表达的可能性显著增加,得分更高 (得分为0的5%对得分为53%).

结论:

血纤维素,吸烟史和SUVmax是肺癌中高PD-L1表达的重要预测因素.
这些发现为识别可能受益于新辅助ICI治疗的患者提供了基础,而不需要进行广泛的手术前生物标志物测试.
开发的预测得分为新辅助疗法选择中的临床决策提供了一个实用的工具.

关键词:

这是一辆SUVmax,SUVmax.非小细胞肺癌的肺癌.血纤维素原体的产生编程细胞死亡连接体 1 编程细胞死亡连接体

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...